2014.09.12 update

【News】Scope of clinical study of HAL ® for Medical Use expanded to include spinal cord disease

CYBERDYNE (hereinafter the Company) was informed that the scope of the target diseases for the domestic investigator-initiated clinical study of the Company’s Robot Suit HAL® for Medical Use (*NCY-2001 test) was expanded in order to verify its clinical effect mainly on paraplegia with spasticity such as human T lymphotropic virus type-1 (HTLV-1) -associated myelopathy in addition to the previously targeted, “intractable neuromuscular diseases”.   
The relevant clinical study was started today (September 12, 2014) at Niigata National Hospital and several medical institutions will follow suit.

cf.) Extract from the website of Japan Intractable Diseases Information Center
(Translated by CYBERDYNE Inc.)
From September 2014, the clinical study (NCY-2001) will be started in order to verify the remedial effect of the gait training program with HAL-HN01 on ambulation disability caused by spastic paraplegia, such as HTLV-1-associated myelopathy (HAM) and other diseases. (Released on August 28, 2014.) (only in Japanese)